Biweekly mXELIRI versus FOLFIRI in combination with bevacizumab as the first-line treatment for metastatic colorectal cancer (EXIST): A multicenter, randomized, open-label, phase 2 study.

Zhichao Jiang, Aiping Zhou, Yongkun Sun et al.|Journal of Clinical Oncology|2022

Cited by 0